Regulatory · source year

2017 regulatory records

41 selected, source-linked regulatory records dated 2017. This is selective source coverage, not a complete timeline.

Dated records

41 selected records.

Peptide profiles

19 connected profiles.

Cited sources

41 distinct public records.

Cited chronology

Dated source records

All record types in 2017 →

December 2017

3 records

Octreotide

Federal Register notice 2017-25920

The Federal Register published notice 2017-25920, attributed to FDA and its parent HHS department, on 2017-12-01. Its official title is “Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

Source: Federal Register via GovInfo ↗

→

November 2017

3 records

October 2017

10 records

Semaglutide

Federal Register notice 2017-21176

The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

Glucagon + 2 more

Federal Register notice 2017-21202

The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.

Source: Federal Register via GovInfo ↗

→

September 2017

3 records

August 2017

4 records

Desmopressin

Federal Register notice 2017-16581

The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

July 2017

2 records

June 2017

5 records

Leuprolide + 1 more

Federal Register notice 2017-12908

The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→

May 2017

4 records

Liraglutide

Federal Register notice 2017-10326

The Federal Register published notice 2017-10326, attributed to FDA and its parent HHS department, on 2017-05-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

April 2017

2 records

March 2017

1 record

February 2017

3 records

January 2017

1 record